Edition:
United States

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

782.25INR
24 Mar 2017
Change (% chg)

Rs-7.65 (-0.97%)
Prev Close
Rs789.90
Open
Rs794.90
Day's High
Rs795.75
Day's Low
Rs778.75
Volume
271,227
Avg. Vol
772,181
52-wk High
Rs832.75
52-wk Low
Rs285.00

Latest Key Developments (Source: Significant Developments)

Jubilant Life Sciences' generic drug for fungal infection gets FDA nod
Monday, 27 Feb 2017 02:42am EST 

Jubilant Life Sciences Ltd : Says Jubilant Life Sciences receives ANDA approval for itraconazole capsules .Says itraconazole capsules is the generic version of Sporanox which is used for the treatment of fungal infections.  Full Article

Jubilant Life Sciences gets ANDA approval for Darifenacin ER tablets
Thursday, 13 Oct 2016 02:11am EDT 

Jubilant Life Sciences Ltd :Says Jubilant Life Sciences receives ANDA approval for Darifenacin ER tablets.  Full Article

Jubilant Life Sciences gets Australian approval for Lyophilized kit
Tuesday, 4 Oct 2016 11:46pm EDT 

Jubilant Life Sciences Ltd :Says Jubilant receives Australian approval for Lyophilized kit for the preparation of Tc 99m MAA injection.  Full Article

Jubilant Life Sciences says unit to issue high yield bonds outside India
Friday, 23 Sep 2016 12:21am EDT 

Jubilant Life Sciences Ltd : Approved the proposal to launch a benchmark offering of unsecured high yield bonds outside India by JPL .The notes are proposed to be listed on the Singapore Exchange Securities Trading Limited.  Full Article

Jubilant Life Sciences gets ANDA approval for felodipine ER tablets
Wednesday, 24 Aug 2016 10:35pm EDT 

Jubilant Life Sciences Ltd : Jubilant Life Sciences receives ANDA approval for Felodipine ER tablets .  Full Article

Jubilant Life Sciences gets ANDA approval for telmisartan tablets
Tuesday, 23 Aug 2016 11:15pm EDT 

Jubilant LifeSciences Ltd : Jubilant Life Sciences receives ANDA approval for telmisartan tablets .  Full Article

Jubilant Life Sciences June-qtr consol profit up about 23 pct
Tuesday, 9 Aug 2016 05:30am EDT 

Jubilant Life Sciences Ltd : June-quarter consol net profit 1.62 billion rupees; consol net sales 14.01 billion rupees . Consol net profit in June quarter last year was 1.32 billion rupees as per Ind-AS; consol net sales was 14.26 billion rupees . Further company coverage [JULS.NS] ((Bangalore.newsroom@thomsonreuters.com)).  Full Article

Jubilant Biosys enters into out-licensing agreement with Checkpoint Therapeutics for Novel BET inhibitors
Friday, 27 May 2016 07:30am EDT 

Jubilant Life Sciences Ltd : Enters into exclusive out licensing agreement with Checkpoint Therapeutics for novel bet inhibitors . Co, Checkpoint Therapeutics sign worldwide license agreement . Jubilant Biosys will out-license to checkpoint a family of patents covering compounds that inhibit brd4 .Deal includes up-front payment of $2 million, contingent preclinical, clinical, regulatory payments.  Full Article

Jubilant Life Sciences unit signs licensing deal with Checkpoint Therapeutics
Thursday, 26 May 2016 10:45pm EDT 

Jubilant Life Sciences Ltd : Jubilant Biosys enters into exclusive out - licensing agreement with Checkpoint Therapeutics for novel BET inhibitors . The deal includes an upfront payment of US $2 million and contingent preclinical, clinical and regulatory payment . Jubilant Biosys will also receive research funding and royalty payments on successful commercialization of the compounds . Checkpoint will assume all further preclinical, clinical development and commercialization responsibilities .  Full Article

Jubilant Life Sciences gets ANDA approval for 0.9% sodium chloride injection USP
Wednesday, 25 May 2016 01:39am EDT 

Jubilant Life Sciences Ltd : Jubilant Life Sciences receives ANDA approval for 0.9% sodium chloride injection USP .  Full Article

More From Around the Web

BRIEF-Jubilant Life Sciences arm Jubilant Pharma to explore buying specialty pharma business in U.S.

* Board of Jubilant Pharma has approved to negotiate a potential acquisition of a specialty pharma business in U.S. Source text: http://bit.ly/2nMv0o8 Further company coverage: